Oncology Advisory Cmte. To Review Unfulfilled Accelerated Approval Trials

FDA's Oncologic Drugs Advisory Committee will review products with unfulfilled accelerated approval postmarketing commitments during an upcoming meeting

More from Archive

More from Pink Sheet